Amarin to Present at Two Upcoming Investor Conferences
June 01, 2023 16:30 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Aaron Berg, Amarin’s Interim President and Chief Executive Officer...
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
June 01, 2023 06:00 ET
|
Amarin Corporation plc
-- VASCEPA Approved by the National Medical Products Administration (NMPA) as an Adjunct to Diet to Reduce Triglyceride Levels in Adult Patients with Severe Hypertriglyceridemia (≥ 500 mg/dL) -- ...
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
May 12, 2023 11:00 ET
|
Amarin Corporation plc
— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — --Data Further Advances Understanding of VASCEPA/VAZKEPA Potential...
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
May 03, 2023 07:00 ET
|
Amarin Corporation plc
-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives -- -- Early Progress in Launch of VAZKEPA® (icosapent ethyl) in England & Wales;...
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
April 19, 2023 08:00 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with Aaron Berg, Interim President...
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
April 17, 2023 07:00 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg,...
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
April 04, 2023 08:00 ET
|
Amarin Corporation plc
-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in...
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
March 16, 2023 08:00 ET
|
Amarin Corporation plc
New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are Working with Urgency to Address Issues at Amarin DUBLIN, Ireland and BRIDGEWATER, N.J., March 16,...
Amarin Announces Board Departures
March 06, 2023 16:05 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER. N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that, in the interest of the Company to...
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
March 06, 2023 08:00 ET
|
Amarin Corporation plc
--In Vitro Data Presentations Support Antithrombotic and Antioxidant Effects of EPA Compared with DHA, No Impact of Mineral Oil on Rates of LDL Oxidation -– DUBLIN, Ireland and BRIDGEWATER, N.J.,...